文献速递免疫规划传染病防控与疫情报告

鼠疫双途径疫苗接种及其紧急使用应用

Dual route vaccination for plague with emergency use applications.
PubMed 文献 · Vaccine · 2018-07-14

本文报道一种鼠疫双途径疫苗接种策略(VypVaxDuo),由重组F1和V蛋白自由结合组成,采用皮下初免疫后单次口服加强免疫,在Balb/c小鼠中可诱导早期免疫并在口服加强后25天对2×10⁴倍半数致死量鼠疫耶尔森菌Co92皮下攻击达到完全保护效力,疫苗瓶装制剂在热应激条件下稳定,无需冷链。

要点

  • VypVaxDuo为重组F1和V蛋白自由结合的双途径鼠疫疫苗,皮下初免疫后单次口服加强。
  • Balb/c小鼠在口服加强后25天对2×10⁴倍半数致死量鼠疫耶尔森菌Co92皮下攻击达到完全保护效力。
  • 初免疫后14天诱导早期免疫,有效诱导血清IgG及血清和粪便IgA。

核心结论

  • 该双途径疫苗接种可诱导快速系统性及黏膜免疫反应,适用于资源匮乏的疫情暴发地区,并适合进一步开发以预防腺鼠疫及在肺鼠疫模型中进行评价。

研究设计与样本

  • 本文报道一种新型疫苗VypVaxDuo(重组F1和V蛋白自由结合),设计为皮下初免疫剂量后单次口服加强剂量,并在Balb/c小鼠中评价免疫原性和对鼠疫耶尔森菌Co92的攻击保护效力。

主要发现

  • VypVaxDuo在初免疫后14天诱导早期免疫。
  • Balb/c小鼠在口服加强免疫后25天,对2×10⁴倍半数致死量鼠疫耶尔森菌Co92皮下攻击达到完全保护效力。
  • 该双途径疫苗有效诱导针对F1和V的血清IgG以及血清和粪便IgA。
  • 瓶装初免疫疫苗制剂在热应激条件下(40°C持续29周,以及40°C、75%相对湿度持续6周)观察到 exceptional 稳定性。

关键数值与推荐

  • 攻击剂量为2×10⁴倍半数致死量鼠疫耶尔森菌Co92,经皮下途径,在口服加强免疫后25天。
  • 热应激条件为40°C持续29周,以及40°C、75%相对湿度持续6周。

临床怎么用

  • 临床使用时,注射用初免疫剂量通过双筒注射器简单复水干粉后给药,后续单次加强剂量以肠溶胶囊形式提供,适合口服自我给药。
  • 原文指出该疫苗无需冷链储存或分发。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Here, we report a dual-route vaccination approach for plague, able to induce a rapid response involving systemic and mucosal immunity, whilst also providing ease of use in those resource-poor settings most vulnerable to disease outbreaks. This novel vaccine (VypVaxDuo) comprises the recombinant F1 and V proteins in free association. VypVaxDuo has been designed for administration via a sub-cutaneous priming dose followed by a single oral booster dose and has been demonstrated to induce early onset immunity 14 days after the primary immunisation; full protective efficacy against live organism challenge was achieved in Balb/c mice exposed to 2 × 104 median lethal doses of Yersinia pestis Co92, by the sub-cutaneous route at 25 days after the oral booster immunisation. This dual-route vaccination effectively induced serum IgG and serum and faecal IgA, specific for F1 and V, which constitute two key virulence factors in Y. pestis, and is therefore suitable for further development to prevent bubonic plague and for evaluation in models of pneumonic plague. This is an essential requirement for control of disease outbreaks in areas of the world endemic for plague and is supported further by the observed exceptional stability of the primary vaccine formulation in vialled form under thermostressed conditions (40 °C for 29 weeks, and 40 °C with 75% relative humidity for 6 weeks), meaning no cold chain for storage or distribution is needed. In clinical use, the injected priming dose would be administered on simple rehydration of the dry powder by means of a dual barrel syringe, with the subsequent single booster dose being provided in an enteric-coated capsule suitable for oral self-administration.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Moore BD, New RRC, Butcher W, et al. Dual route vaccination for plague with emergency use applications. Vaccine. 2018. PMID: 30017148. doi:10.1016/j.vaccine.2018.06.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。